Chiesi Farmaceutici S.p.A. (Chiesi Global Rare Diseases)

Chiesi Global Rare Diseases is a business unit of the privately held, family-owned Chiesi Group, an international research-focused biopharmaceutical company. Established in February 2020, this unit is dedicated to the research, development, and commercialization of innovative therapies and solutions for people living with rare and ultra-rare diseases. Its mission is to address significant unmet medical needs and improve the quality of life for patients globally. While the parent company, Chiesi Farmaceutici S.p.A., is headquartered in Parma, Italy, Chiesi Global Rare Diseases operates with its primary base in Boston, Massachusetts.

The unit's therapeutic focus spans a range of complex conditions, including lysosomal diseases, endometabolic disorders, ophthalmology, dermatology, hematology, and immunology. Key products and areas of development target diseases such as Fabry Disease, Alpha-mannosidosis, Nephropathic Cystinosis, Thalassemia, Leber's Hereditary Optic Neuropathy (LHON), and Hereditary Angioedema (HAE). Notable products in its portfolio include Filsuvez for rare skin diseases and Elfabrio, an enzyme replacement therapy.

Chiesi Global Rare Diseases has demonstrated significant growth and strategic expansion through acquisitions and partnerships. In a notable recent development, the Chiesi Group announced in April 2026 its largest acquisition to date: KalVista Pharmaceuticals for approximately $1.9 billion, expected to close in Q3 2026. This acquisition will integrate Ekterly (sebetralstat), an oral, on-demand treatment for HAE, into its rare disease portfolio. Led by Executive Vice President Giacomo Chiesi, the unit aims to substantially contribute to the Chiesi Group's strategic revenue target of €6 billion by 2030, reinforcing its market position in rare diseases.